Your session is about to expire
← Back to Search
Entospletinib for Acute Myeloid Leukemia
Study Summary
This trial will compare the effectiveness of a new drug, entospletinib, to a placebo when given with standard chemotherapy to patients with a specific type of acute myeloid leukemia who have not been treated before. The primary outcome measure will be the rate of molecularly defined measurable residual disease.
- NPM1-mutated Acute Myeloid Leukemia
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 & 2 trial • 24 Patients • NCT03010358Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Could you tell me if this experiment is available to people who are less than 60 years old?
"In order to be a part of this study, individuals must be between 18-74 years old. Out of the 527 clinical trials available for patients under 18 and 1371 for those over 65, this is the only one that meets these age requirements."
If I qualify, may I take part in this experiment?
"This clinical trial is looking for 180 participants total, who currently have leukemia, myeloid, acute. The patients must also meet the following criteria: be between 18 and 74 years old, have untreated de novo acute myeloid leukemia (AML), AML with myelodysplastic syndromes (MDS) features, or therapy-related AML,, be a candidate for intensive induction therapy., Nucleophosmin-1 (NPM1)-mutated disease documented in a local or the Sponsor's central testing facility., Note: Participants with local test results for nucleophosmin-1"
Are there any open positions for test subjects in this experiment?
"From what is available on clinicaltrials.gov, it appears that this particular trial is open for recruitment. The initial posting was on 11/30/2021 with the most recent update taking place on 10/24/2022."
How many people are being asked to participate in this clinical trial?
"One hundred and eighty individuals that fit the pre-determined inclusion criteria are necessary for this clinical trial. Eligible patients have the opportunity to participate at Princess Margaret Cancer Centre in Toronto, South carolina or Hollings Cancer Center in Charleston, Texas."
What are the primary medical conditions that Entospletinib has been shown to improve?
"leptomeningeal metastases can often be treated with Entospletinib. This pharmaceutical is also effective against acute promyelocytic leukemia, meningeal leukemia, and blast phase chronic myelocytic leukemia."
Are there other precedents for Entospletinib's therapeutic effect?
"As of now, there are 251 live studies researching Entospletinib with 62 trials in Phase 3. While most of the clinical trials for Entospletinib are based in Providence, Rhode island, there are 9883 locations operating clinical trials for Entospletinib."
In how many different areas is this experiment being conducted today?
"So far, this clinical trial has recruited patients from Princess Margaret Cancer Centre in Toronto, South carolina, Hollings Cancer Center in Charleston, Texas, and St. Francis Cancer Center in Greenville, Indiana with 14 other locations currently being scouted."
Are there long-term repercussions to taking Entospletinib?
"There is some data that entospletinib is efficacious and it has undergone multiple rounds of testing for safety, so it received a score of 3."
Share this study with friends
Copy Link
Messenger